Home
/
Atea Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Atea Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Atea Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2022
Sep 30, 2021
$32.81M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$60.39M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$65.99M
May 10, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($42.05M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($37.16M)
Aug 7, 2025
Q3
2025
Jun 30, 2025
($37.16M)
Nov 12, 2025
Q1
2025
Mar 31, 2025
($34.27M)
May 12, 2025
Q3
2025
Mar 31, 2025
($34.27M)
Nov 12, 2025
Q2
2025
Mar 31, 2025
($34.27M)
Aug 7, 2025
Q3
2025
Sep 30, 2024
($31.15M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($40.52M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($40.52M)
Nov 12, 2025
Q3
2025
Mar 31, 2024
($63.17M)
Nov 12, 2025
Q1
2025
Mar 31, 2024
($63.17M)
May 12, 2025
Q2
2025
Mar 31, 2024
($63.17M)
Aug 7, 2025
Q3
2024
Sep 30, 2023
($33.14M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($28.18M)
Aug 7, 2024
Q3
2024
Jun 30, 2023
($28.18M)
Nov 7, 2024
Q2
2024
Mar 31, 2023
($35.47M)
Aug 7, 2024
Q3
2024
Mar 31, 2023
($35.47M)
Nov 7, 2024
Q1
2024
Mar 31, 2023
($35.47M)
May 14, 2024
Q3
2023
Sep 30, 2022
($8.07M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($31.34M)
Aug 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($45.57M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($41.35M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($39.04M)
May 12, 2025
Q3
2025
Sep 30, 2024
($37.20M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($46.92M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($69.81M)
May 12, 2025
Q3
2024
Sep 30, 2023
($40.79M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($35.24M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($41.57M)
May 14, 2024
Q3
2023
Sep 30, 2022
($16.28M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($32.30M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($42.18M)
May 8, 2023
Q3
2022
Sep 30, 2021
($22.15M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
$8.69M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$30.66M
May 10, 2022
Q3
2021
Sep 30, 2020
($17.63M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($10.00M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($4.05M)
May 13, 2021
Q3
2020
Sep 30, 2019
($3.77M)
Dec 10, 2020